Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 by Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri,

Slides:

Advertisements

Similar presentations

Allogeneic stem cell transplantation for adult Philadelphia chromosome–negative acute lymphocytic leukemia: comparable survival rates but different risk.

Advertisements

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia by Nathalie Dhédin, Anne Huynh, Sébastien.

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.

Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse.

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year.

Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics between Acute Myelogenous.

Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.

Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow.

Gupta V, Tallman MS, Weisdorf DJ

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood.

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis Marie Robin, Federica Giannotti, Eric Deconinck, Mohamad Mohty,

Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience by Régis Peffault.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study.

Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity.

Role of primacy of birth in HLA-identical sibling transplantation

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine,

Donor Selection for Killer Immunoglobulin-like Receptors B Haplotype of the Centromeric Motifs Can Improve the Outcome after HLA-Identical Sibling Hematopoietic.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous.

Biology of Blood and Marrow Transplantation

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise,

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases by John A. Snowden, Manuela Badoglio,

Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-Up of a Randomized Study Tapani Ruutu,

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Risk Factors for Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience Aazim K. Omer, Panayiotis.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen by Haris Ali, Ibrahim Aldoss, Dongyun.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia.

Outcome of Allogeneic Peripheral Blood Stem Cell Transplantation by Donor Graft CD3+/Tregs Ratio: A Single-Center Experience Mario Delia, Domenico Pastore,

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation Ibrahim.

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? by Tara M. Robinson, Ephraim J. Fuchs,

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study by Salyka Sengsayadeth, Katie.

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute.

Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients by Jenna Sopfe, Laura Pyle, Amy K.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion Laurent Garderet, Dimitris Ziagkos, Anja van Biezen, Simona.

Bridge to transplant following Bv+Bs regimen.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML by Renato Bassan, Tamara Intermesoli, Arianna.

Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion Franck E. Nicolini, Eric Wattel, Anne-Sophie.

Comparison of Two Doses of Antithymocyte Globulin in Patients Undergoing Matched Unrelated Donor Allogeneic Stem Cell Transplantation Francis Ayuk, Galina.

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL by Peter Dreger, Anna Sureda, Kwang.

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation.

Presentation transcript:

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 by Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri, Gerard Socie, Depei Wu, Liisa Volin, Didier Blaise, Noel Milpied, Charles Craddock, Ibrahim Yakoub-Agha, Johan Maertens, Per Ljungman, Anne Huynh, Mauricette Michallet, Eric Deconinck, Patrice Chevallier, Jakob Passweg, Fabio Ciceri, Mohamad Mohty, Jan J. Cornelissen, and Arnon Nagler BloodAdv Volume 1(7):477-485 February 28, 2017 © 2017 by The American Society of Hematology

Jurjen Versluis et al. Blood Adv 2017;1:477-485 © 2017 by The American Society of Hematology

Outcome by different donor types. Outcome by different donor types. Kaplan-Meier estimates of OS (A), RFS (B), relapse (C), and NRM (D) by donor type of patients with poor-risk AML in CR1. F, number of failures (ie, death whatever the cause); Cox LR, Cox likelihood ratio. Jurjen Versluis et al. Blood Adv 2017;1:477-485 © 2017 by The American Society of Hematology